Gujarat Terce Laboratories Limited has secured trading approval from BSE for 3,71,000 equity shares allotted through warrant conversion on preferential basis. The pharmaceutical company informed the exchange about receiving the trading approval for shares issued to promoter Mr. Aalap Prajapati.

Share Allotment Details

The trading approval covers equity shares with specific parameters as outlined by BSE:

Trading Commencement

BSE issued the trading approval through letter bearing reference number LOD/PREF/SV/394/2025-2026 dated February 24, 2026. The exchange confirmed that trading in these securities would commence effectively from Wednesday, February 25, 2026. The approval was communicated to trading members through BSE Notice No. 20260224-9 dated February 24, 2026.

Regulatory Compliance

The company made the disclosure pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations. Company Secretary Ms. Ashka Solanki signed the intimation letter, ensuring compliance with regulatory requirements for informing stakeholders about the trading approval.

Financial Impact

The warrant conversion represents a significant capital infusion for the company:

The preferential allotment to the promoter strengthens the company's equity base while maintaining promoter participation in the business growth.

Gujarat Terce Laboratories Limited has reported its unaudited standalone financial results for the third quarter ended December 31, 2025, showing a decline in both revenue and profitability compared to the corresponding period last year. The pharmaceutical company's Board of Directors approved these results at their meeting held on February 4, 2026.

Financial Performance Overview

The company's quarterly performance reflected challenging market conditions, with key metrics showing year-on-year declines across major parameters.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Gujarat Terce Laboratories recorded revenue from operations of ₹3,607.34 lakhs compared to ₹3,787.08 lakhs in the corresponding period of the previous year, representing a decline of 4.75%. Total revenue for the nine-month period stood at ₹3,633.58 lakhs against ₹3,809.18 lakhs in 9MFY25.

Operational Metrics and Cost Structure

The company's expense structure for Q3FY26 totaled ₹1,129.21 lakhs compared to ₹1,177.04 lakhs in Q3FY25. Employee benefit expenses remained the largest cost component at ₹403.29 lakhs for the quarter, slightly higher than ₹397.73 lakhs in the previous year. Purchase of stock in trade was ₹283.40 lakhs, marginally lower than ₹284.44 lakhs in Q3FY25.

Finance costs showed improvement, declining to ₹3.99 lakhs from ₹8.45 lakhs year-on-year. Other expenses decreased to ₹261.93 lakhs from ₹313.14 lakhs in the corresponding quarter of the previous year.

Regulatory Compliance and Corporate Governance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone limited review by the company's statutory auditor, Shah Doshi Patel & Associates LLP. The results comply with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The company operates in a single pharmaceutical segment, and the paid-up equity capital stood at ₹779.13 lakhs as of December 31, 2025, compared to ₹742.03 lakhs in the previous year. The Board meeting commenced at 3:00 p.m. IST and concluded at 4:05 p.m. IST on February 4, 2026.